Literature DB >> 3493015

High-dose corticosteroids as adjunct therapy in severe Pneumocystis carinii pneumonia.

W el-Sadr, G Sidhu, G Diamond, A Zuger, D Berman, M S Simberkoff, J J Rahal.   

Abstract

Three patients with severe Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome, not responding to specific therapy with trimethoprim/sulfamethoxazole, were treated with a 24-hour course of high-dose methylprednisolone. Rapid improvements in the clinical status and the chest X-rays were detected. In two of the patients, in whom lung biopsy was performed before initiation of corticosteroids, an intense interstitial mononuclear cell infiltrate was seen. In the one patient who had lung biopsy after corticosteroid therapy, a scanty amount of mononuclear cells was demonstrated in the interstitium. Our experience suggests that corticosteroids may be useful as adjunctive agents in the treatment of severe P. carinii pneumonia not responding to specific anti-Pneumocystis therapy. This may be a result of inhibition of mononuclear cell accumulation within the lung by the steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3493015     DOI: 10.1089/aid.1.1986.2.349

Source DB:  PubMed          Journal:  AIDS Res        ISSN: 0737-6006


  3 in total

1.  Optimising technetium 99m diethylene triamine penta-acetate lung clearance in patients with the acquired immunodeficiency syndrome.

Authors:  H Van der Wall; I P Murray; P D Jones; D W Mackey; B M Walker; P Monaghan
Journal:  Eur J Nucl Med       Date:  1991

Review 2.  Aids and the lung. 6-- Management of respiratory failure in patients with the acquired immune deficiency syndrome and Pneumocystis carinii pneumonia.

Authors:  R F Miller; D M Mitchell
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

3.  Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex.

Authors:  S Brooke; R Chan; S Howard; R Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.